Madrigal Pharmaceuticals, Inc. (MDGL) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong financial performance with a 35% increase in net sales and a solid cash position. The new patent protection and pipeline development, including the combination therapy for MASH, suggest long-term growth potential. Despite increased expenses, the strategic focus on market expansion and the optimistic guidance on MAESTRO outcomes provide a positive outlook. The Q&A reveals confidence in competitive positioning and access, though some ambiguity remains. Overall, the sentiment leans positive, likely leading to a stock price increase.
Key Financial Performance
Net Sales $287.3 million for Q3 2025, up 35% quarter-over-quarter. The increase is attributed to strong demand driven by positive response to Rezdiffra from prescribers and patients, and strong execution by the team.
R&D Expenses $174 million for Q3 2025, compared to $68.7 million in Q3 2024. The increase is primarily due to a one-time $117 million expense associated with the global licensing agreement for MGL-2086.
SG&A Expenses $209.1 million for Q3 2025, compared to $107.6 million in Q3 2024. The increase reflects higher commercial investment to support the Rezdiffra launch.
Cash Position $1.1 billion at the end of Q3 2025. The increase reflects the $350 million initial term loan under the senior secured credit facility, partially offset by the funding of operations.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Rezdiffra sales: Rezdiffra sales are annualizing at over $1 billion in its sixth quarter of launch, with net sales of $287 million in Q3 2025, up 35% quarter-over-quarter.
Patient adoption: More than 29,500 patients are on Rezdiffra therapy, up from 23,000 in the previous quarter. Over 10,000 healthcare providers have prescribed it.
Pipeline development: Advancing Phase III MAESTRO-NASH outcomes trial in F4c and planning a Phase I trial for a new oral GLP-1 (MGL-2086) in combination with Rezdiffra.
Global expansion: Rezdiffra launched in Germany following European approval, with a country-by-country approach to expand in Europe.
Market positioning: Rezdiffra targets 315,000 diagnosed patients with moderate to advanced fibrosis, with 90% of the target population untreated. Novo's Wegovy approval in MASH is expected to raise awareness and expand the market.
Payer contracting: Progressing well with 2026 payer contracts for broad first-line access, no step edits, and improved utilization management criteria. Contracts expected to be finalized by year-end.
Gross-to-net management: Gross-to-net impact expected to increase to the high 30% range in 2026, consistent with other specialty medicines.
Strategic focus: Focused on top-line growth and pipeline expansion, including combination therapies and new mechanisms for MASH treatment.
Business development: Acquired an oral GLP-1 (MGL-2086) to develop in combination with Rezdiffra, aiming for a best-in-disease oral therapy.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Market Competition: The entry of competitors like Novo with Wegovy in the MASH market could increase competition and potentially impact Rezdiffra's market share. While Novo targets a broader population, their presence may drive awareness but also intensify competitive pressures.
Regulatory and Payer Challenges: While progress has been made in payer negotiations, there is still a dependency on finalizing contracts for 2026. Any delays or unfavorable terms could impact patient access and revenue growth.
Supply Chain and Launch Execution: The company is expanding globally, including a launch in Germany. However, scaling operations and ensuring effective physician education and system wiring in new markets could pose logistical and operational challenges.
Economic and Financial Risks: The company has incurred significant R&D and SG&A expenses, including a one-time $117 million expense for a licensing agreement. This increases financial pressure and reliance on continued revenue growth to sustain operations.
Pipeline Development Risks: The success of the pipeline, including the Phase III MAESTRO-NASH outcomes trial and the development of the oral GLP-1 combination, is critical. Delays or failures in these programs could hinder long-term growth and market leadership.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Rezdiffra Patient Growth: The company expects to continue steadily adding patients to Rezdiffra therapy, with more than 90% of the 315,000 target population remaining untreated, indicating substantial growth potential.
Market Evolution for MASH: The MASH market is expected to evolve into a multibillion-dollar category, similar to other chronic disease markets like IBD and psoriasis, driven by innovation and tailored treatment regimens.
Payer Contracting for 2026: The company anticipates finalizing payer contracts by the end of 2025, ensuring broad first-line access to Rezdiffra with no step edit requirements and improved utilization management criteria. Gross to net impact is expected to be in the high 30% range starting in 2026.
European Expansion: Rezdiffra launched in Germany in September 2025, with efforts to expand access across Europe expected to make an impact in 2026.
Pipeline Development: The company plans to start a Phase I trial for its new oral GLP-1 (MGL-2086) in the first half of 2026, aiming to develop a best-in-disease combination therapy with Rezdiffra.
MAESTRO-NASH Outcomes Trial: The Phase III MAESTRO-NASH outcomes trial in compensated MASH cirrhosis (F4c) is expected to read out in 2027, potentially making Rezdiffra the first approved therapy for F4c.
Gross to Net Management: Gross to net impact for Rezdiffra is projected to be at the midpoint of 20%-30% in Q4 2025 and increase to the high 30% range in 2026, consistent with other specialty medicines.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How does the 2-year data, especially the NIT-driven responses, derisk the MAESTRO-NASH outcome expected in 2028?
A:The open-label cohort from the MAESTRO NAFLD study shows sustained efficacy of Rezdiffra on liver stiffness and biomarkers, giving confidence in the MAESTRO outcomes. The patient populations in the open-label cohort and MAESTRO outcomes are similar, supporting the expectation of positive trial results.
Q:What are the pros and cons of combining resmetirom with MGL-2086 versus other oral GLP-1s like orforglipron?
A:Combining resmetirom with GLP-1s like orforglipron enhances efficacy due to weight loss benefits. Other mechanisms are also being explored for potential combinations, focusing on scientific rationale and patient advantage. The company is casting a wide net for the best opportunities.
Q:What are Madrigal's thoughts on its competitive positioning and market access in light of recent M&A in the MASH space?
A:Madrigal views recent M&A as validation of the MASH market. They believe their long-term strategy, including Rezdiffra's IP until 2045 and their pipeline, positions them as leaders in the space. They anticipate their data will be competitive and aim for long-term leadership in MASH.
Q:Can you confirm Rezdiffra's adherence rate and discuss its net pricing dynamics?
A:Rezdiffra's adherence rate is in the 60%-70% range, consistent with well-tolerated orals. Net pricing is expected to decline over time due to contracting effects, but the company is achieving broad first-line access and improved utilization management criteria.
Q:What is the impact of Aetna's formulary decision on Rezdiffra's access?
A:Aetna's decision not to include Rezdiffra on its formulary for 2026 is unchanged from 2025. Patients can still access the drug through prior authorization or medical exception, with no practical change in access.
Q:Has Novo's marketing campaign broadened the pool of addressable patients for Rezdiffra?
A:It is too early to quantify the impact of Novo's campaign. Madrigal continues to see steady patient additions and believes increased diagnosis efforts by Novo could benefit the market overall. The target population of 315,000 diagnosed patients remains relevant.
Q:What is the path to profitability for Madrigal given the successful launch of Rezdiffra?
A:Madrigal is focused on driving top-line growth and building its pipeline. Profitability is not an immediate focus, but the company is steadily adding patients and achieving robust sales growth.
Q:How does Rezdiffra's profile support its potential as a long-term chronic therapy?
A:Rezdiffra's once-a-day pill format, tolerability, and sustained efficacy make it well-suited for long-term chronic use. Real-world evidence supports its effectiveness, and its profile is considered ideal for chronic therapy.
Q:What is the expected cadence for the EU launch of Rezdiffra, and how will it impact growth?
A:The EU launch began in Germany in Q3 2025 with minimal revenue impact. Growth in 2026 will be predominantly driven by U.S. sales, with Europe contributing modestly as the system is built out country by country.
Q:Are there systemic differences in insurance approval rates for Rezdiffra based on the prescribing physician's specialty?
A:Insurance approval rates vary by payer, with most requiring prescriptions from specialists like hepatologists or gastroenterologists. Some plans may include endocrinologists. Madrigal focuses on specialists for prescribing Rezdiffra.
Q:Review of Unclear Management Responses
A:Management avoided directly addressing Sagimet's plans for testing denifanstat with Rezdiffra, stating they have no knowledge of Sagimet's plans and are not involved in such combinations. Additionally, they did not provide specific metrics or targets for depth in marketing strategy or reconcile patient numbers with revenue figures, leaving some ambiguity in these areas.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AASLD week
CSPH
III NASH
MASH
MGL
NASH outcome
Phase III
Rezdiffra Slide
Rezdiffra patent
Rezdiffra profile
Slide progress
access Rezdiffra
access patient
approach
choice patient
cohort AASLD
combination
expense
label cohort
launch milestone
line access
loss Rezdiffra
mechanism treatment
metabolic
midpoint
milestone prescribers
monotherapies
multibillion dollar
outcome trial
patient Rezdiffra
patient provider
payer contracting
practice
reduction
resmetirom
value
weight loss
MDGL Transcript
Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-10
Madrigal Pharmaceuticals, Inc. (MDGL) Q1 2026 Earnings Call Transcript
Unknown5-6
The earnings call highlights a 25% revenue increase and reduced net loss, which are positive indicators. However, the lack of discussion on strategic initiatives, operational updates, or shareholder returns limits the positive impact. The increase in R&D expenses and slight decrease in cash reserves are neutral factors, balancing the overall sentiment. The absence of Q&A insights further supports a neutral stance. Without additional context on market cap or strategic developments, the stock price is likely to remain stable, resulting in a neutral prediction.
Madrigal Pharmaceuticals, Inc. (MDGL) Q4 2025 Earnings Call Transcript
Positive2-19
The earnings call highlights strong financial performance, strategic product development, and optimistic market strategies. Despite some uncertainties in the European market, the company shows robust growth potential, especially in the U.S. The Q&A session indicates positive analyst sentiment and confidence in future growth. The strategic focus on expanding patient numbers and maintaining high adherence rates supports a positive outlook. However, the absence of specific guidance and European market uncertainties slightly temper the overall sentiment.
Madrigal Pharmaceuticals, Inc. (MDGL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-13
MDGL Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
